retatrutide clinical trial availability VisualAbstract: reduces body weight by 17.5% in patients with obesity retatrutide clinical trials safety The

Despite YoY growth exceeding 100%, Tirzepatides quarter-over-quarter growth slowed to just 13%, indicating the market might soon shift into a stock competition phase

Rev Clin Esp

We do have: 10+ year safety data for earlier GLP-1 agonists (liraglutide, exenatide) Growing evidence of cardiovascular benefits from weight loss medications Understanding that obesity itself has well-documented health risks The risk-benefit calculation often favors treatment, but this is an individual decision that should be made with your healthcare provider based on your specific medical situation

FIB-4 cut-off of 1.3 may be inappropriate in a primary care referral pathway for patients with NAFLD

Wang, Y

Ill also share practical ways to structure your offerings so you can support womens weight loss with integrity and long-term impact